Literature DB >> 8005189

Nonlinear kinetics of nortriptyline in relation to nortriptyline clearance as observed during therapeutic drug monitoring.

M Jerling1, G Alván.   

Abstract

From routine therapeutic drug monitoring data, samples from 105 patients with two analyses of nortriptyline at different daily doses were collected. The ratio between concentration and daily dose, which is the reciprocal of the apparent clearance, was compared intra-individually to study the occurrence of dose-dependent kinetics. Subjects with a low or intermediate ratio at the low dose had a higher mean ratio at the high dose, indicating a nonlinear relationship between dose and concentration. The magnitude of the difference was inversely correlated to the ratio at the low dose. No major difference was seen in the ca. 10% of the patients that exhibited the highest ratio at the low dose. This fraction corresponds to the frequency of poor metabolizers of debrisoquine in the population. The metabolism of nortriptyline has been shown to be partly dependent on the debrisoquine hydroxylase CYP2D6. We conclude that dose-dependent kinetics of nortriptyline occurs in subjects with a high or intermediate capacity to eliminate the drug, in accord with debrisoquine hydroxylase being a high-affinity, low-capacity pathway in the elimination of nortriptyline.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005189     DOI: 10.1007/BF00195918

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.

Authors:  S H Sindrup; K Brøsen; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1992-03       Impact factor: 6.875

2.  Nonlinear kinetics of nortriptyline in every day practice.

Authors:  S Vandel; G Bertschy; B Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

4.  Relationship between dose and plateau levels of drugs eliminated by parallel first-order and capacity-limited kinetics.

Authors:  T Tsuchiya; G Levy
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

5.  Dose-dependent kinetics of imipramine in elderly patients.

Authors:  M Bjerre; L F Gram; P Kragh-Sørensen; C B Kristensen; O L Pedersen; M Møller; P Thayssen
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

7.  Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.

Authors:  L Bertilsson; M Eichelbaum; B Mellström; J Säwe; H U Schulz; F Sjöqvist
Journal:  Life Sci       Date:  1980-11-03       Impact factor: 5.037

8.  Amitriptyline: linear or nonlinear kinetics in every day practice?

Authors:  S Vandel; G Bertschy; B Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics.

Authors:  K Brøsen; L F Gram; R Klysner; P Bech
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  9 in total
  4 in total

Review 1.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

2.  Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response.

Authors:  M Jerling
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

3.  Quantitative pharmacogenetics of nortriptyline: a novel approach.

Authors:  E E Kvist; A Al-Shurbaji; M L Dahl; C Nordin; G Alván; L Ståhle
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.

Authors:  M Jerling; Y Merlé; F Mentré; A Mallet
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.